Name (Synonyms) | Correlation | |
---|---|---|
drug780 | Cospherunate/Azythromycine Wiki | 1.00 |
drug781 | Cospherunate/Phytomedicine/Azythromycien Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D006973 | Hypertension NIH | 0.26 |
D002318 | Cardiovascular Diseases NIH | 0.19 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0000822 | Hypertension HPO | 0.26 |
HP:0001626 | Abnormality of the cardiovascular system HPO | 0.19 |
There is one clinical trial.
The phase II clinical trial, with three arms and at rate of 10 patients per arm, received the approval of the National Committee for Ethics and Health Research. This is a non inferiority test aimed to compare the efficacy and safety in add on to Azithromycin, an antimalarial drug, a treatment combination of the antimalrial drug with an antiviral phytomedicine versus Hydroxychloroquine in COVID-19 patients without complications. During the treatment, viral clearance, adverse effects related to treatment, and symptoms progression will be assessed on days 3, 6 and 14. Clinical, paraclinical and laboratory tests will be performed throughout the 3-month trial. Ethical and deontological considerations will be applied.
Description: Virological clearance from admission to discharge at days 3, 6 and 14
Measure: Virological clearance of throat swabs or lower respiratory tract secretions Time: day 3 to day 14Description: number of patients who developed treatment-related adverse effects
Measure: Adverse effects Time: day 1 to day 14Description: number of patients whose conditions worsened
Measure: Worsened conditions Time: day 1 to day 14Description: number of patients whose fever, cough and any other clinical sign observed on introduction have resolved
Measure: COVID-19 symptoms Time: day 1 to day 14